Canine adenovirus type 2 vectors (CAV-2) are promising tools to treat global central nervous system (CNS) disorders because of their preferential transduction of neurons and efficient retrograde axonal transport. Here we tested the potential of a helper-dependent CAV-2 vector expressing β-glucuronidase (HD-RIGIE) in a mouse model of mucopolysaccharidosis type VII (MPS VII), a lysosomal storage disease caused by deficiency in β-glucuronidase activity. MPS VII leads to glycosaminoglycan accumulation into enlarged vesicles in peripheral tissues and the CNS, resulting in peripheral and neuronal dysfunction. After intracranial administration of HD-RIGIE, we show long-term expression of β-glucuronidase that led to correction of neuropathology around the injection site and in distal areas. This phenotypic correction correlated with a decrease in secondary-elevated lysosomal enzyme activity and glycosaminoglycan levels, consistent with global biochemical correction. Moreover, HD-RIGIE-treated mice show significant cognitive improvement. Thus, injections of HD-CAV-2 vectors in the brain allow a global and sustained expression and may have implications for brain therapy in patients with lysosomal storage disease.
Get full access to this article
View all access options for this article.
References
1.
BirkenmeierE.H., DavissonM.T., BeamerW.G., et al. (1989). Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest., 83, 1258–1266.
2.
BoschA., PerretE., DesmarisN., and HeardJ.M. (2000a). Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther., 1, 63–70.
3.
BoschA., PerretE., DesmarisN., et al. (2000b). Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther., 11, 1139–1150.
4.
CaoH., YangT., LiX.F., et al. (2011). Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Ther., 18, 173–181.
5.
CardoneM., PolitoV.A., PepeS., et al. (2006). Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum. Mol. Genet., 15, 1225–1236.
6.
ChenY.H., ClaflinK., GeogheganJ.C., and DavidsonB.L. (2012). Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol. Ther., 20, 1393–1399.
7.
ChirmuleN., PropertK., MagosinS., et al. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther., 6, 1574–1583.
8.
CironC., DesmarisN., ColleM.A., et al. (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol., 60, 204–213.
9.
CraneB., LuoX., DemasterA., et al. (2012). Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia. Gene Ther., 19, 443–452.
10.
CressantA., DesmarisN., VerotL., et al. (2004). Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci., 24, 10229–10239.
11.
DimmockD., Brunetti-PierriN., PalmerD.J., et al. (2011). Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors. Hum. Gene Ther., 22, 483–488.
12.
DindotS., PiccoloP., GroveN., et al. (2011). Intrathecal injection of helper-dependent adenoviral vectors results in long-term transgene expression in neuroependymal cells and neurons. Hum. Gene Ther., 22, 745–751.
13.
EllinwoodN.M., AusseilJ., DesmarisN., et al. (2011). Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther., 19, 251–259.
14.
EngC.M., GuffonN., WilcoxW.R., et al. (2001). Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N. Engl. J. Med., 345, 9–16.
15.
Gimenez-LlortL., Fernandez-TeruelA., EscorihuelaR.M., et al. (2002). Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci., 16, 547–550.
16.
Gimenez-LlortL., BlazquezG., CaneteT., et al. (2007). Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci. Biobehav. Rev., 31, 125–147.
17.
GrabowskiG.A., LeslieN., and WenstrupR. (1998). Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev., 12, 115–133.
18.
HarmatzP., GiuglianiR., SchwartzI., et al. (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr., 148, 533–539.
19.
KakkisE.D., MuenzerJ., TillerG.E., et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med., 344, 182–188.
20.
KerielA., ReneC., GalerC., et al. (2006). Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J. Virol., 80, 1487–1496.
21.
KremerE.J., BoutinS., ChillonM., and DanosO. (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol., 74, 505–512.
22.
Langford-SmithA., WilkinsonF.L., Langford-SmithK.J., et al. (2012). Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol. Ther., 20, 1610–1621.
23.
LauA.A., RozaklisT., IbanesS., et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene, 491, 53–57.
24.
LeBowitzJ.H., GrubbJ.H., MagaJ.A., et al. (2004). Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA, 101, 3083–3088.
25.
LevyB., GalvinN., VoglerC., et al. (1996). Neuropathology of murine mucopolysaccharidosis type VII. Acta Neuropathol., 92, 562–568.
26.
LiuG., MartinsI., WemmieJ.A., et al. (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci., 25, 9321–9327.
27.
LiuG., ChenY.H., HeX., et al. (2007). Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol. Ther., 15, 242–247.
28.
LowensteinP.R., MandelR.J., XiongW.D., et al. (2007). Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther., 7, 347–360.
29.
MooreD.J., MarkmannJ.F., and DengS. (2006). Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transpl. Int., 19, 435–445.
30.
MuenzerJ. (2011). Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl., 5, v4–v12.
31.
MuhammadA.K., XiongW., PuntelM., et al. (2012). Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum. Gene Ther. Methods, 23, 271–284.
32.
O'ConnorL.H., ErwayL.C., VoglerC.A., et al. (1998). Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J. Clin. Invest., 101, 1394–1400.
33.
PerreauM., and KremerE.J. (2005). Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J. Virol., 79, 14595–14605.
34.
PerreauM., GuerinM.C., DrouetC., and KremerE.J. (2007a). Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol. Ther., 15, 1998–2007.
35.
PerreauM., MennechetF., SerratriceN., et al. (2007b). Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J. Virol., 81, 3272–3284.
36.
SalinasS., BilslandL.G., HenaffD., et al. (2009). CAR-associated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog., 5, e1000442.
37.
SardielloM., PalmieriM., di RonzaA., et al. (2009). A gene network regulating lysosomal biogenesis and function. Science, 325, 473–477.
38.
SchagenF.H., RademakerH.J., RabelinkM.J., et al. (2000). Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther., 7, 1570–1574.
39.
SchuldtA.J., HamptonT.J., ChuV., et al. (2004). Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc. Natl. Acad. Sci. USA, 101, 603–608.
40.
SeokJ., WarrenH.S., CuencaA.G., et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA, 110, 3507–3512.
41.
ShipleyJ.M., KlinkenbergM., WuB.M., et al. (1993). Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. Am. J. Hum. Genet., 52, 517–526.
42.
SlyW.S., VoglerC., GrubbJ.H., et al. (2001). Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice. Proc. Natl. Acad. Sci. USA, 98, 2205–2210.
43.
SoperB.W., LessardM.D., VoglerC.A., et al. (2001). Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood, 97, 1498–1504.
44.
SotakB.N., HnaskoT.S., RobinsonS., et al. (2005). Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res., 1061, 88–96.
45.
SoudaisC., Laplace-BuilheC., KissaK., and KremerE.J. (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J., 15, 2283–2285.
46.
SoudaisC., SkanderN., and KremerE.J. (2004). Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J., 18, 391–393.
47.
ThomasC.E., BirkettD., AnozieI., et al. (2001). Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther., 3, 36–46.
48.
ThurbergB.L., Lynch MaloneyC., VaccaroC., et al. (2006). Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest., 86, 1208–1220.
49.
VoglerC., LevyB., KyleJ.W., et al. (1994). Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod. Pathol., 7, 132–137.
50.
VoglerC., SandsM.S., GalvinN., et al. (1998). Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J. Inherit. Metab. Dis., 21, 575–586.
51.
WilcoxW.R., BanikazemiM., GuffonN., et al. (2004). Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet., 75, 65–74.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
